Outlook Therapeutics grants CEO, CFO options at $1.43 per share
OTLK•Executive compensation tied to FDA decision on ONS-5010
Outlook Therapeutics set new executive compensation tied to a near-term FDA decision on ONS-5010 (bevacizumab-vikg).
- Granted stock options on July 21, 2026: CEO Robert C. Jahr 100,000 options; CFO Lawrence A. Kenyon 210,078 options.
- Options carry a $1.43 exercise price; vest July 21, 2027, contingent on continued service.
- Authorized cash bonuses of $420,000 for Jahr, $200,000 for Kenyon, payable only if FDA approval occurs by July 31, 2026.
